Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort

The 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies patients with chronic obstructive pulmonary disease (COPD) into four groups (A to D). We explored the characteristics, stability and relationship to outcomes of these groups within the ECLIPSE study (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) (n = 2101). Main results showed that: 1) these groups differed in several clinical, functional, imaging and biological characteristics in addition to those used for their own definition; 2) A and D groups were relatively stable over time, whereas groups B and C showed more temporal variability; 3) the risk of exacerbation over 3 years increased progressively from A to D, whereas that of hospitalisation and mortality were lowest in A, highest in D and intermediate and similar in B and C, despite the former having milder airflow limitation. The prevalence of comorbidities and persistent systemic inflammation were highest in group B. The different longitudinal behaviour of group A versus B and C versus D (each pair with similar forced expiratory volume in1 s (FEV1) values supports the 2011 GOLD proposal of assessing COPD patients by more than FEV1 only. However the assumption that symptoms do not equate to risk appears to be naïve, as groups B and C carry equally poor clinical outcomes, though for different reasons. Exploring distribution, characteristics, temporal stability and relationship with 2011 GOLD group outcomes in ECLIPSE http://ow.ly/mjJ8p

[1]  Edwin K. Silverman,et al.  Chronic obstructive pulmonary disease , 2012, Nature Reviews Disease Primers.

[2]  Edwin K Silverman,et al.  GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. , 2013, The Lancet. Respiratory medicine.

[3]  Ciro Casanova,et al.  Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification. , 2013, Chest.

[4]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[5]  Satoshi Konno,et al.  Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.

[6]  Morten Dahl,et al.  Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. , 2012, American journal of respiratory and critical care medicine.

[7]  Ciro Casanova,et al.  Distribution and prognostic validity of the new GOLD grading classification. , 2012 .

[8]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[9]  Ciro Casanova,et al.  The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. , 2011, American journal of respiratory and critical care medicine.

[10]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[11]  D. Postma,et al.  A new perspective on optimal care for patients with COPD. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[12]  E. Regan,et al.  Genetic Epidemiology of COPD (COPDGene) Study Design , 2011, COPD.

[13]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[14]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[15]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[16]  D. Mannino,et al.  Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.

[17]  W. MacNee,et al.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.

[18]  M. Gonen,et al.  Concordance probability and discriminatory power in proportional hazards regression , 2005 .

[19]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[20]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[21]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[22]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[23]  M. Stulbarg,et al.  OBSTRUCTIVE PULMONARY DISEASE: The Clinician's Perspective , 1998 .

[24]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[25]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[26]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[27]  P. O'Byrne,et al.  Is nedocromil sodium effective treatment for asthma? , 1993, The European respiratory journal.

[28]  Buist As.  Standardization of spirometry. , 1987 .

[29]  Williams Mh,et al.  OBSTRUCTIVE PULMONARY DISEASE , 1964 .

[30]  A. R. Jonckheere,et al.  A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES , 1954 .